Noriyuki Kasahara Net Worth

What's Noriyuki Kasahara's mailing address?

Noriyuki's mailing address filed with the SEC is C/O 4D MOLECULAR THERAPEUTICS, INC., 5858 HORTON STREET #455, EMERYVILLE, CA, 94608.

Insiders trading at 4D Molecular Therapeutics

Over the last 4 years, insiders at 4D Molecular Therapeutics have traded over 22,158,915$ worth of 4D Molecular Therapeutics stock and bought 2,479,347 units worth 51,074,981$ . The most active insiders traders include Global Investors Lp Viking ...、John F Milligan、Global Investors Lp Viking .... On average, 4D Molecular Therapeutics executives and independent directors trade stock every 36 days with the average trade being worth of 1,516,666$. The most recent stock trade was executed by Scott Bizily on 19 August 2024, trading 500 units of FDMT stock currently worth 3,245$.

What does 4D Molecular Therapeutics do?

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; Benitec; CRF; Roche; CFF; and AstraZeneca. The company was founded in 2013 and is headquartered in Emeryville, California.

4D Molecular Therapeutics executives and stock owners

4D Molecular Therapeutics executives and other stock owners filed with the SEC include:

• Dr. David H. Kirn,
  Co-Founder, CEO, Pres & Director
• August J. Moretti Esq., J.D.,
  Chief Financial Officer
• August J. Moretti,
  Chief Financial Officer
• Dr. Robert S. Fishman,
  Chief Medical Officer & Therapeutic Area Head of Pulmonology
• Dr. David E. Schaffer Ph.D.,
  Co-Founder, Chief Scientific Advisor & Independent Director
• Dr. John F. Milligan,
  Exec. Chairman
• Dr. Nadine Greiner Ph.D.,
  Chief HR Officer
• Dr. Scott P. Bizily J.D., Ph.D.,
  Chief Legal Officer
• Dr. Raphael Schiffmann M.D.,
  Sr. VP & Therapeutic Area Head of Cardiology
• Jessica Wilan,
  Sr. VP of HR
• Dr. Peter Francis B.Sc., M.D., Ph.D.,
  Chief Scientific Officer & Head of Ophthalmology Therapeutic Area
• Dr. Fred Kamal Ph.D.,
  COO & CTO
• Theresa Janke,
  Co-Founder & Chief Strategy Officer
• Scott Bizily,
  Chief Legal Officer
• August J Moretti,
  Chief Financial Officer
• Tony Dung Ling Yao,
  Director
• Noriyuki Kasahara,
  Director
• Carolyne Zimmermann,
  Chief Business Officer
• Robert Young Kim,
  Chief Medical Officer
• Fariborz Kamal,
  President and COO
• Uneek Mehra,
  See Remarks
• David Schaffer,
  Director
• Robert S Fishman,
  Chief Medical Officer
• John F Milligan,
  
• Susannah Gray,
  
• Nancy Miller Rich,
  
• David Kirn,
  Chief Executive Officer
• Jacob Chacko,
  
• Global Investors Lp Viking ...,
  
• Charles Theuer,
  
• Shawn Tomasello,